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Abstract
  Cancer survivor is de ned all persons who ever received a diagnosis of cancer. Because of advances in early detection 
and treatment, cancer has become a curable disease for some and a chronic illness for others. Since the number of cancer survi-
vors is increasing, physicians have more opportunities to treat them. Good pain control signi cantly improves the QOL of can-
cer survivors.
  Although WHO analgesic ladder is the principle of pain treatment, drug treatment should be carried out according to the 
non-cancer chronic pain treatment if they had been expected longer survival time. Using both long-term and high-dose opioid 
analgesics possibly cause opioid-induced hyperalgesia, opioid dependence, abuse and addiction. If the physician continue the 
opioid therapy, they should prepare both adequate follow-up and appropriate education for the patients. Since most of the 
cancer survivor’s pain has the character of neuropathic pain, it is very necessary to use adequate analgesic adjuvant. In 
addition, the pain in cancer survivors is a holistic, holistic palliative approach should be necessary. Together with the drug 
therapy and palliative approach, multimodal intervention therapy involved nerve block and interventional therapy is 
recommended. 
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